Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations

BRAF(V600E) melanoma patients, despite initially responding to the clinically prescribed anti-BRAF(V600E) therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAF(V600E) mutation, they often eventually diverge a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:NPJ Precis Oncol
Huvudupphovsmän: Vasudevan, S., Flashner-Abramson, E., Alkhatib, Heba, Roy Chowdhury, Sangita, Adejumobi, I. A., Vilenski, D., Stefansky, S., Rubinstein, A. M., Kravchenko-Balasha, N.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2021
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8192524/
https://ncbi.nlm.nih.gov/pubmed/34112933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00190-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk